(Total Views: 323)
Posted On: 01/09/2020 10:36:38 AM
Post# of 36566
All that negativity on the table, here is what I hope happens in the next 2 months (I'm guessing this would be similar to Joe's hopes/plans):
1) The lynch pin, in my mind: NGIO spins, adding significant value and liquidity to GNBT, driving up the GNBT share price
2) The S-1 gets approved and priced at a reasonable SP (due to the NGIO asset driver), keeping dilution to a minimum.
3) The $ from the S-1 is used to close the AltuCell deal, fund the Olaregen deal/propel Excellagen into a revenue-generating machine, pay off ill-termed debt.
4) $ from the S-1 starts to turn the wheels in AZ, Veneto, Pantheon, Medisource, AltuCell, etc.
5) There are no new companies brought into the fold for a year while the kinks are worked out and GNBT has all the details worked out in the current "family" of companies.
6) NGIO has a successful Ph II, begins to move on the buccal delivery system and its potential uses.
7) 2019 is a distant memory.
1) The lynch pin, in my mind: NGIO spins, adding significant value and liquidity to GNBT, driving up the GNBT share price
2) The S-1 gets approved and priced at a reasonable SP (due to the NGIO asset driver), keeping dilution to a minimum.
3) The $ from the S-1 is used to close the AltuCell deal, fund the Olaregen deal/propel Excellagen into a revenue-generating machine, pay off ill-termed debt.
4) $ from the S-1 starts to turn the wheels in AZ, Veneto, Pantheon, Medisource, AltuCell, etc.
5) There are no new companies brought into the fold for a year while the kinks are worked out and GNBT has all the details worked out in the current "family" of companies.
6) NGIO has a successful Ph II, begins to move on the buccal delivery system and its potential uses.
7) 2019 is a distant memory.
(5)
(0)
